Kazi Tutul: According to the World Health Organization 2012, an estimated 22 million deaths worldwide are due to diabetes. (1) Of which the number of diabetic patients in 2019 was 1 crore. The study says it will double by 2045. (2) According to the American Diabetes Association, an American spends about 16752 a year on treatment for diabetes. More than a thousand rupees. These figures highlight the dire economic and health status of diabetes. However, in this system, a patient has to take insulin injections once or more than once a day. Diabetes treatment costs and injecting insulin. Excessive use of insulin and its effectiveness are questioning the current medical system. According to the World Health Organization (WHO), 90-95 percent of diabetic patients worldwide suffer from diabetes. And 80 percent of these patients live in underdeveloped and developing countries. So 80 percent of people can’t get proper treatment for diabetes.
To overcome all the complications related to the treatment of diabetes, a team of scientists from Bangladesh, India and South Korea have been researching a gene called Glucagon-Like-Peptide-1 (GLP-1) for a long time. The study was conducted at the National University of Transportation, Career Institute of Science and Technology, South Korea, and was led by Shatil Shahriar, a Bangladeshi researcher. No need to take through. Rather, it can be taken orally as a tablet or capsule. It will work for a long time in very small doses. In order to make the treatment of diabetes easier and to bring the cost of treatment of diabetes within the reach of patients in underdeveloped and developing countries. It will work against all the side effects of diabetes. As these symptoms are impossible with the current injection-dependent medical system, the research team was more interested in gene therapy rather than working with new drug molecules, said Shatil Shahriar. Normally, a drug works just as much as it enters the bloodstream. But the genetic transcription of the GLP-1 gene is a technique for introducing DNA into cells that can make the necessary antibodies from the body’s cells.
The research paper was recently published by “Nano Letters”, one of the most famous communications in the world. This elite class journal of the American Chemical Society claims that a team of researchers led by Bangladeshi researcher Shatil Shahriar has developed an oral antidote for diabetes, a combination of gene therapy and nanotechnology. The most important aspect of this study is that this antidote will be more effective and efficient than the widely used insulin in controlling diabetes. The patient needs to be on an empty stomach before taking insulin. It is not necessary to take this antidote. This antidote does not need to be injected more than once a day like insulin. Able to work in one dose for up to a month.
So the cost of diabetes treatment will be within the reach of people. And you do not have to endure the unbearable pain of injections every day. A healthy person While insulin is made and can work in the body, this antidote can work similarly in the body of a diabetic patient. This is where the difference lies in this antidote to insulin. Active insulin will be made in the body of the diabetic patient. So there is no need to inject insulin repeatedly. Just as a healthy person’s body produces enough insulin when its blood glucose levels rise, so too will a diabetic’s body produce the amount of insulin it needs to take revenge. So now the patient does not have to face any complications related to overdose of insulin.
The famous journal “Nano Letters” says that this low dose of insulin not only makes insulin or controls blood glucose level in the long run but also diabetics who are in the last stage of diabetes. It works against a variety of side effects of diabetes, including weight gain, liver damage, heart disease and hypertension.
This oral dose, taken in just a few doses, is able to reduce the appetite and thirst of the brain through the hypothalamus and reduce the tendency to eat repeatedly, as well as increase the fullness and satiety of food intake. Excessive levels of triglycerides in the blood can destroy pancreatic cells, including heart disease, stroke, and high blood pressure, and reduce the risk of triglyceride levels by up to 50 percent in diabetics, “the study found.
The US Food and Drug Administration (FDA) recently recognized two antidote trulicity (trulicity) and tenzeum (tanzium) that can control diabetes by activating the cell’s GLP-1 receptor. Remains stationary. Studies show that in a clinical trial, an oral antidote is seven times more effective than an injection of the US FDA-approved antidote Trulycity. (4) In addition, according to the FDA, 50 mg per kg body weight of diabetic monkeys is effective in clinical trials of transzium injections. Since insulin and GLP are produced from the body by taking the antidote, it is hoped that these two antidepressants approved by the FDA will only work in injection doses. But the discovery of this antidote in very small doses in an oral dosage is effective in the journal Allometric Principles that it will control the blood glucose of the human body for up to a month.
Studies in rats, monkeys, and other parts of the human body have shown that this antidote, a drug called Glucagon Peptide (GLP-1) without side effects, has been approved by the US Food and Drug Administration. The American Chemical Society claims that it can.